Epacria Capital Partners’s Maravai LifeSciences MRVI Stock Holding History

Epacria Capital Partners’s Portfolio MRVI Stock Details MRVI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-100,078	Closed	-$283K	–	30
2026 Q1	$283K	Hold	100,078	–	–	0.22%	27
2025 Q4	$325K	Hold	100,078	–	–	0.26%	29
2025 Q3	$287K	Buy	100,078 +6,384	+7%	+$16.3K	0.23%	28
2025 Q2	$226K	Buy	93,694 +38,264	+69%	+$80.4K	0.19%	32
2025 Q1	$122K	Buy	+55,430	New	+$219K	0.1%	39

Other funds holding MRVI

GTCR LLC Chicago, Illinois $3.91B AUM 14.64% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return

1WCM

12 West Capital Management New York $535M AUM 25.99% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

OAM

Ophir Asset Management Sydney, Australia $1.22B AUM 100.03% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

First Eagle Investment Management New York $60.8B AUM 26.63% 1-Year Est. Return

Epacria Capital Partners's MRVI Position: Q2 2026 in Review

Epacria Capital Partners sold out of Maravai LifeSciences (MRVI) in Q2 2026, closing a stake of 100,078 shares — an estimated $283K sold.

Epacria Capital Partners first reported a position in MRVI in Q1 2025 and held it in 5 quarters. The position peaked at $325K in Q4 2025. 177 funds tracked by Wall St. Rank hold MRVI as of Q2 2026.

Epacria Capital Partners reported no remaining Maravai LifeSciences position as of Q2 2026 after selling out during the quarter.
Epacria Capital Partners sold 100,078 Maravai LifeSciences shares in Q2 2026, an estimated $283K.
Epacria Capital Partners first reported a position in Maravai LifeSciences in Q1 2025 and held it in 5 quarters.
Epacria Capital Partners's Maravai LifeSciences position peaked at $325K in Q4 2025.
177 funds tracked by Wall St. Rank held Maravai LifeSciences as of Q2 2026.

Based on Epacria Capital Partners's 13F filing for Q2 2026, filed 14 Aug 2026.